{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Johnson NA"],"funding":["Medical Research Council","NCI NIH HHS"],"pagination":["2273-9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2745846"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["114(11)"],"pubmed_abstract":["BCL2 and MYC are oncogenes commonly deregulated in lymphomas. Concurrent BCL2 and MYC translocations (BCL2(+)/MYC(+)) were identified in 54 samples by karyotype and/or fluorescence in situ hybridization with the aim of correlating clinical and cytogenetic characteristics to overall survival. BCL2(+)/MYC(+) lymphomas were diagnosed as B-cell lymphoma unclassifiable (BCLU; n = 36) with features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL); DLBCL (n = 17), or follicular lymphoma (n = 1). Despite the presence of a t(14;18), 5 cases were BCL2 protein-negative. Nonimmunoglobulin gene/MYC (non-IG/MYC) translocations occurred in 24 of 54 cases (44%) and were highly associated with DLBCL morphology (P < .001). Over a median follow-up of 5.3 years, 6 patients remai"],"journal":["Blood"],"pubmed_title":["Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival."],"pmcid":["PMC2745846"],"funding_grant_id":["MC_U132670597","UO1-CA84967-1","U01 CA084967"],"pubmed_authors":["Ben-Neriah S","Siebert R","Connors JM","Savage KJ","Woods R","Klasa R","Ludkovski O","Kuruvilla J","Steidl C","Johnson NA","Gascoyne RD","Dyer MJ","Horsman DE"],"additional_accession":[]},"is_claimable":false,"name":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.","description":"BCL2 and MYC are oncogenes commonly deregulated in lymphomas. Concurrent BCL2 and MYC translocations (BCL2(+)/MYC(+)) were identified in 54 samples by karyotype and/or fluorescence in situ hybridization with the aim of correlating clinical and cytogenetic characteristics to overall survival. BCL2(+)/MYC(+) lymphomas were diagnosed as B-cell lymphoma unclassifiable (BCLU; n = 36) with features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL); DLBCL (n = 17), or follicular lymphoma (n = 1). Despite the presence of a t(14;18), 5 cases were BCL2 protein-negative. Nonimmunoglobulin gene/MYC (non-IG/MYC) translocations occurred in 24 of 54 cases (44%) and were highly associated with DLBCL morphology (P < .001). Over a median follow-up of 5.3 years, 6 patients remai","dates":{"release":"2009-01-01T00:00:00Z","publication":"2009 Sep","modification":"2026-03-16T16:54:33.609Z","creation":"2025-09-01T03:06:37.554Z"},"accession":"S-EPMC2745846","cross_references":{"pubmed":["19597184"],"doi":["10.1182/blood-2009-03-212191"]}}